Aurélie Olivier

894 total citations
16 papers, 399 citations indexed

About

Aurélie Olivier is a scholar working on Epidemiology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aurélie Olivier has authored 16 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 7 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aurélie Olivier's work include Respiratory viral infections research (6 papers), Pneumonia and Respiratory Infections (4 papers) and Inflammation biomarkers and pathways (3 papers). Aurélie Olivier is often cited by papers focused on Respiratory viral infections research (6 papers), Pneumonia and Respiratory Infections (4 papers) and Inflammation biomarkers and pathways (3 papers). Aurélie Olivier collaborates with scholars based in Belgium, France and United States. Aurélie Olivier's co-authors include Anne Galy, Evelyne Lauret, Patrick Gonin, Claude Leclerc, Paul M. Tulkens, Françoise Van Bambeke, Sandrine Lemaire, Florence Boisgérault, Sandra Hervás‐Stubbs and Nathalie Thiéblemont and has published in prestigious journals such as Blood, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Aurélie Olivier

14 papers receiving 393 citations

Peers

Countries citing papers authored by Aurélie Olivier

Since Specialization

Citations

This map shows the geographic impact of Aurélie Olivier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Olivier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Olivier more than expected).

Fields of papers citing papers by Aurélie Olivier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélie Olivier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Olivier. The network helps show where Aurélie Olivier may publish in the future.

Co-authorship network of co-authors of Aurélie Olivier

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Olivier. A scholar is included among the top collaborators of Aurélie Olivier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Olivier. Aurélie Olivier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial 2025 ·The Lancet Respiratory Medicine ·Michael G. Ison, Alberto Papi, Eugene Athan, Robert G. Feldman, Joanne M. Langley, Dong‐Gun Lee, Isabel Leroux‐Roels, Federico Martinón‐Torres, Tino F. Schwarz, Richard N. van Zyl-Smit, (unknown), (unknown), Nancy Dezutter, Catherine Gérard, Laurence Fissette, (unknown), (unknown), Aurélie Olivier, Marie Van der Wielen, Dominique Descamps, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	12
2	Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial 2024 ·Clinical Infectious Diseases ·(unknown), (unknown), (unknown), (unknown), Sophie Germain, Sherine Kuriyakose, (unknown), Dominique Descamps, Aurélie Olivier, Veronica Hulstrøm	19
3	Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults 2024 ·Vaccine X ·Murdo Ferguson, Alexander G. Murray, (unknown), Lars Rombo, Johan Berglund, Marie‐Pierre David, Nathalie De Schrevel, (unknown), Shady Kotb, Aurélie Olivier, Veronica Hulstrøm	1
4	Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial 2023 ·The Journal of Infectious Diseases ·Tino F. Schwarz, (unknown), (unknown), Chiu-Shong Liu, Kenji Takazawa, Makoto Yono, John Ervin, Charles P. Andrews, Charles Fogarty, (unknown), Delphine Collete, Magali de Heusch, Nathalie De Schrevel, Bruno Salaun, (unknown), Céline Maréchal, Aurélie Olivier, (unknown), Marc Lievens, Veronica Hulstrøm	16
5	1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons 2023 ·Open Forum Infectious Diseases ·Michael G. Ison, Alberto Papi, Joanne M. Langley, Dong‐Gun Lee, Isabel Leroux‐Roels, Federico Martinón‐Torres, Tino F. Schwarz, Richard N. van Zyl-Smit, (unknown), Nancy Dezutter, Olivier Gruselle, Laurence Fissette, Marie‐Pierre David, Aurélie Olivier, Marie Van der Wielen, Dominique Descamps	4
6	2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults 2022 ·Open Forum Infectious Diseases ·(unknown), (unknown), (unknown), Dean Quinn, (unknown), Mohammed Bensellam, Nathalie De Schrevel, Sherine Kuriyakose, (unknown), Aurélie Olivier, Veronica Hulstrøm	0
7	Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial 2021 ·BMJ Open ·Bruno François, Simon Lambden, Sébastien Gibot, Marc Derive, Aurélie Olivier, Valérie Cuvier, Stephan Witte, Jean‐Marie Grouin, (unknown), (unknown), Mitchell M. Levy, Pierre‐François Laterre	11
8	Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial 2020 ·Intensive Care Medicine ·Bruno François, Xavier Wittebole, Ricard Ferrer, Jean‐Paul Mira, Thierry Dugernier, Sébastien Gibot, Marc Derive, Aurélie Olivier, Valérie Cuvier, Stephan Witte, Peter Pickkers, François Vandenhende, Jean–Jacques Garaud, Miguel Sánchez, (unknown), Pierre‐François Laterre	46
9	A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition 2018 ·British Journal of Clinical Pharmacology ·Valérie Cuvier, Ulrike Lorch, Stephan Witte, Aurélie Olivier, Sébastien Gibot, Isabelle Delor, Jean–Jacques Garaud, Marc Derive, (unknown)	29
10	The adjuvant effect of TLR agonists on CD4⁺ effector T cells is under the indirect control of regulatory T cells 2011 ·European Journal of Immunology ·Aurélie Olivier, (unknown), Hui Dong, Tim Sparwasser, Laleh Majlessi, Claude Leclerc	16
11	Role ofrsbUand Staphyloxanthin in Phagocytosis and Intracellular Growth ofStaphylococcus aureusin Human Macrophages and Endothelial Cells 2009 ·The Journal of Infectious Diseases ·Aurélie Olivier, Sandrine Lemaire, Françoise Van Bambeke, Paul M. Tulkens, Eric Oldfield	40
12	Restoration of Susceptibility of Intracellular Methicillin-ResistantStaphylococcus aureusto β-Lactams: Comparison of Strains, Cells, and Antibiotics 2008 ·Antimicrobial Agents and Chemotherapy ·Sandrine Lemaire, Aurélie Olivier, Françoise Van Bambeke, Paul M. Tulkens, Peter C. Appelbaum, Y. Glupczynski	22
13	TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help 2007 ·Blood ·Sandra Hervás‐Stubbs, Aurélie Olivier, Florence Boisgérault, Nathalie Thiéblemont, Claude Leclerc	48
14	A Partial Down-regulation of WASP Is Sufficient to Inhibit Podosome Formation in Dendritic Cells 2005 ·Molecular Therapy ·Aurélie Olivier, Laurence Jeanson-Leh, Gerben Bouma, Daniel Compagno, Johanna Blondeau, (unknown), Sabine Charrier, Siobhan O. Burns, Adrian J. Thrasher, Olivier Danos, William Vainchenker, Anne Galy	39
15	Variation in morphology and performance of predator-sensing system in wild cricket populations 2005 ·Journal of Experimental Biology ·Olivier Dangles, Christelle Magal, Dominique Pierre, Aurélie Olivier, Jérôme Casas	43
16	The Notch ligand delta-1 is a hematopoietic development cofactor for plasmacytoid dendritic cells 2005 ·Blood ·Aurélie Olivier, Evelyne Lauret, Patrick Gonin, Anne Galy	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact